Biphasic Insulin Aspart 30 Therapy in Insulin-Naïve and Insulin-Experienced Patients with Type 2 Diabetes: Results from the Jordanian Subgroup of the A1chieve Study

Autor:	Jihad Haddad, Firas Abbas Annabi, Abdel-Ellah Al-Shudifat, Rashad Nasser, Moawia Al-Kilani, Levent Sandalci, Fares Haddad
Rok vydání:	2014
Předmět:	Diabetes duration medicine.medical_specialty Glycated haemoglobin-A1c business.industry Insulin medicine.medical_treatment Insulin naive Type 2 diabetes medicine.disease Biphasic insulin aspart Internal medicine medicine Drug reaction business Body mass index
Zdroj:	Journal of Diabetes Mellitus. :379-387
ISSN:	2160-5858 2160-5831
Popis:	Objective: To analyse the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in a Jordanian subgroup of the 24-week, non-interventional A1chieve study. Methods: A total of 509 Jordanian patients with type 2 diabetes (392 insulin-naive and 117 insulin-experienced) starting BIAsp30, alone or in combination with oral glucose-lowering drugs, were included. Safety and effectiveness outcomes were analysed over 24 weeks. Results: Patients had a mean age of 55.8 years, body mass index of 28.8 kg/m2 and diabetes duration of 9.4 years at baseline. Two serious adverse drug reactions of hypoglycaemia were reported. The proportion of patients who reported major hypoglycaemic events decreased (2.4% at baseline vs. 0.2% at Week 24, p = 0.0039). The proportion of patients reporting overall hypoglycaemia increased marginally (6.3% at baseline vs. 9.9% at Week 24, p = 0.0378), primarily attributed to a rise in minor and nocturnal hypoglycaemia reported in insulin-naive patients. From baseline to Week 24, the mean ± SD glycated haemoglobin A1c level decreased from 9.8% ± 1.4% to 7.4% ± 0.9% (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::82c08e0bf3da6d410c664c896ac249ca https://doi.org/10.4236/jdm.2014.44051 Zobrazit plný text záznamu